Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference

JAZZ 11.19.2024

Full Press ReleaseSEC FilingsOur JAZZ Tweets

About Gravity Analytica

Recent News

  • 01.14.2025 - Jazz Pharmaceuticals at J.P. Morgan Healthcare Conference
  • 12.17.2024 - Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
  • 12.16.2024 - Jazz Pharmaceuticals Announces CEO Succession Plan

Recent Filings

  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 8-K Current report
  • 01.06.2025 - 4 Statement of changes in beneficial ownership of securities

DUBLIN,Nov. 19, 2024/PRNewswire/ --Jazz Pharmaceuticals plc(Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2024 Global Healthcare Conference. Company management will participate in a fireside chat onTuesday, December 3, 2024, at7:15 a.m. PT/10:15 a.m. ET/3:15 p.m. GMT.

An audio webcast of the fireside chat will be available via the Investors section of theJazz Pharmaceuticalswebsite athttps://investor.jazzpharma.com/investors/events-presentations. A replay of the webcast will be archived on the website for 30 days.

AboutJazz PharmaceuticalsJazz Pharmaceuticals plc(Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered inDublin, Irelandwith research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visitwww.jazzpharmaceuticals.comfor more information.

Contacts:

Investors:Andrea N. Flynn, Ph.D.Vice President, Head, Investor RelationsJazz Pharmaceuticals plcInvestorInfo@jazzpharma.comIreland+353 1 634 3211U.S.+1 650 496 2717

Media:Kristin BhavnaniHead ofGlobal Corporate CommunicationsJazz Pharmaceuticals plcCorporateAffairsMediaInfo@jazzpharma.comIreland+353 1 637 2141U.S.+1 215 867 4948

Jazz Pharmaceuticals Logo (PRNewsFoto/Jazz Pharmaceuticals plc) (PRNewsFoto/Jazz Pharmaceuticals plc)

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-participate-in-citis-2024-global-healthcare-conference-302310546.html

SOURCEJazz Pharmaceuticals plc

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com